title: Cabozantinib approved for advanced medullary thyroid cancer.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D000284:Administration, Oral; D000813:Anilides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009367:Neoplasm Staging; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D011725:Pyridines; C558660:cabozantinib